All In Biotech

Drug Trial Radar · NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Actual

Start

Nov 19, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Conditions

  • Obesity

Interventions

  • ABBV-295Drug

    Subcutaneous Injections

  • PlaceboDrug

    Subcutaneous Injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 194 days
  2. Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 194 days
  3. Number of Participants with Change from Baseline in Electrocardiogram (ECG)Time frame: Up to approximately 194 days
  4. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 194 days
  5. Maximum Observed Plasma Concentration (Cmax) of ABBV-295Time frame: Up to approximately 194 days
  6. Time to Cmax (Tmax) of ABBV-295Time frame: Up to approximately 194 days
  7. Trough plasma concentration (Ctrough) of ABBV-295Time frame: Up to approximately 194 days
  8. Apparent terminal phase elimination rate constant (BETA) of ABBV-295Time frame: Up to approximately 194 days
  9. Terminal phase elimination half-life (t1/2) of ABBV-295Time frame: Up to approximately 194 days
  10. Area under the plasma concentration-time curve (AUC) of ABBV-295Time frame: Up to approximately 194 days
  11. Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295Time frame: Up to approximately 194 days
  12. Dose Normalized Cmax of ABBV-295Time frame: Up to approximately 194 days
  13. Dose Normalized AUC of ABBV-295Time frame: Up to approximately 194 days
  14. Incidence of Anti-Drug Antibodies (ADAs)Time frame: Up to approximately 194 days
  15. Percent Change in Body Weight From BaselineTime frame: Up to approximately 194 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel Act- Anaheim Clinical Trials /ID# 283200

    Anaheim, California

  • Acpru /Id# 278624

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.